Compare EPOW & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPOW | LGVN |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 25.9M |
| IPO Year | 2019 | 2021 |
| Metric | EPOW | LGVN |
|---|---|---|
| Price | $0.48 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 33.8K | ★ 220.5K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $0.48 |
| 52 Week High | $1.86 | $1.23 |
| Indicator | EPOW | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 32.30 | 65.31 |
| Support Level | $0.40 | $0.60 |
| Resistance Level | $0.72 | $0.87 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 9.95 | 88.22 |
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.